Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa "EPO"

Terminated

Phase 4 Results

Eligibility Criteria

Inclusion Criteria

- Patients age 30-75
- Patients undergoing vascular clipping post SAH
- Aneurysmal SAH as determined by history or clinical evaluation
- WFNS Score I and II
- Hb ≤ 12 g/dL within 36 hours prior to first dose of study drug
- Patients who receive Study drug and undergo surgical clipping of the aneurysm within 36 hours of the SAH event

Exclusion Criteria

- Non-aneurysmal SAH
- WFNS Score III and higher
- Patients presenting with previous history of SAH
- Terminal, brain-dead, comfort care patients
- Patients not undergoing vascular clipping
- Hb > 12 g/dL
- Patients receiving blood transfusion prior to surgery
- Patients who currently receive Procrit or an EPO product
- Patients undergoing surgical clipping of the aneurysm greater than 36 hours after the SAH event
- Pregnancy or lactating
- Renal insufficiency (must present and maintain normal creatinine levels)
- Uncontrolled hypertension (systolic > 150 mmHg)
- Active or known seizure history within one year of SAH event
- Known history of thrombotic vascular events (PE, DVT, AMI, stroke)
- Allergy or sensitivity to mammalian derived products